Abound Wealth Management Catalyst Pharmaceuticals, Inc. Transaction History
Abound Wealth Management
- $301 Billion
- Q3 2024
A detailed history of Abound Wealth Management transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Abound Wealth Management holds 10 shares of CPRX stock, worth $239. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10
Previous 12
16.67%
Holding current value
$239
Previous $186,000
6.99%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CPRX
# of Institutions
305Shares Held
98.1MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$447 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$218 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$194 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$144 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$72.2 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.46B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...